Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
What bowel dose constraint do you recommend if you are boosting a pelvic lymph node for prostate cancer?
Do you have a maximum bowel dose constraint?
Answer from: Radiation Oncologist at Community Practice
We generally use 55 Gy to < 5 cc based on Gyne literaturem and try to make sure the high prescribed dose is limited to one wall of bowel loop.
Comments
Radiation Oncologist at Torrance Memorial Medical Center
@Sushil Beriwal, could you share a paper or protoc...
Radiation Oncologist at Varian Medical Systems/Allegheny health network
This is the one I was referring to. It’s a s...
2752
2753
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
60 to 66 Gy at 2 Gy per fraction.
Sign in or Register to read more
6526
6532
Related Questions
How do you manage LUTS in the post-prostatectomy setting?
How do you contour your elective obturator lymph node volume?
For patients with oligo-progressive prostate cancer fit for metastasis-directed therapy but ineligible for radiotherapy or surgery, how do you decide between the types of ablation available?
How do you follow/manage patients with metastatic prostate cancer with undetectable PSA and castration-sensitive but active disease on PSMA PET?
How do you manage PSA progression while a patient is on xofigo or pluvicto?
Can a PSA bounce be seen shortly after SBRT to prostate cancer oligometastases while on androgen deprivation therapy?
Does long term use of 5 alpha reductase inhibitors change the way you evaluate a PSMA PET?
Would you consider treating a patient with prostate cancer and biopsy-proven involved inguinal nodes with radiation to the prostate/pelvis/groin?
In a patient with a synchronous prostate cancer and non-invasive urothelial carcinoma limited to the prostatic urethra is complete TUR and definitive prostate dose to standard prostate fields adequate treatment?
How would you manage T3N0M0 sarcomatoid carcinoma of the prostate with Adenosquamous differentiation s/p prostatectomy?
@Sushil Beriwal, could you share a paper or protoc...
This is the one I was referring to. It’s a s...